Amidst a year of executive changes and several product launches, Bausch + Lomb Corporation is continuing its new developments with the addition of five new executives—including two vice presidents and two newly created roles—to the company’s leadership team.
Let’s start with these new VPs.
Both assuming the role of executive vice president; Asli Gevgilili is taking over as chief human resources (HR) officer, while Al Waterhouse will be the company's chief supply chain and operations officer.
To note, Gevglili is replacing Kelly Webber, the company’s chief HR officer, who is leaving after 35 years in the HR profession.
Give me some background on them.
Gevgilili currently services as the chief human resources officer at INOVIO Pharmaceuticals. He was previously at Allergan, Merck, and Merril Lynch in human resources leadership roles.
Waterhouse previously served as president and CEO of AcuFocus. Other notable past leadership roles include Abbott Medical Optics, Advanced Medical Optics, and PCI Pharma Services.
And this other exec?
The company’s chief compliance officer is Jonathaon Kellerman, who was most recently a partner at Boston Consulting Group (a healthcare compliance practice).
Prior to that, he was Allergan’s chief compliance officer and led PricewaterhouseCoopers’ (PwC) healthcare compliance practice.
Now these two newly created roles.
B+L has created the roles of chief communications officer and chief corporate development and digital officer; T.J. Crawford and Manisha Narasimhan, PhD, have assumed these responsibilities, respectively.
Any other new roles?
One more! The company announced that Dennis Asharin, its current chief global manufacturing and supply chain officer, will take over as head of quality, reporting now to Waterhouse.
When are these effective?
Per B+L, as of August 2023.
Gotcha. What other recent changes have there been?
In June 2023, the company announced a reshaping of its executive leadership team that elevated all business heads. Read more here.
And in February 2023, Brent Saunders was welcomed back as the company’s CEO, which he previously held the same position from 2010 to 2013.
Since his return—and with B+L’s new status as a publicly traded company—his focus has been in establishing the company’s position as a separate company from Bausch Health.
What has the company been up to this year, product-wise?
Quite a lot.
Here’s a rundown of the last few months:
April 2023
May 2023
- FDA approval for MIEBO (in partnership with Novaliq)
June 2023
- Launch of INFUSE multifocal SiHy contact lenses in US
- Launch of Biotrue Hydration Boost CL rehydrating drops
- Launch of PreserVision AREDS 2 formula mini soft gels with CoQ10
- Announcement of Xiidra acquisition (from Novartis)
July 2023